ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Michael S. Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8407-3423; OpenAlex author ID A5088195904. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 26

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers

Papers 3

Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00505-0 ↗
Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II T… Co-author DOI 10.1200/jco.24.00081 ↗
Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities. Co-author DOI 10.1200/edbk_321255 ↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shubham Pant · 3 shared papers, 2021–2024 · strength 0.58
- Paper Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel… DOI 10.1200/edbk_321255 ↗
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0 ↗
- Paper Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEN… DOI 10.1200/jco.24.00081 ↗
Matthew H. G. Katz · 2 shared papers, 2024 · strength 0.30
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0 ↗
- Paper Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEN… DOI 10.1200/jco.24.00081 ↗
Dan Zhao · 2 shared papers, 2024 · strength 0.30
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0 ↗
- Paper Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEN… DOI 10.1200/jco.24.00081 ↗
Jason A. Willis · 2 shared papers, 2024 · strength 0.30
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0 ↗
- Paper Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEN… DOI 10.1200/jco.24.00081 ↗
Robert A. Wolff · 2 shared papers, 2024 · strength 0.30
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0 ↗
- Paper Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEN… DOI 10.1200/jco.24.00081 ↗
Brandon George Smaglo · 2 shared papers, 2024 · strength 0.30
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0 ↗
- Paper Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEN… DOI 10.1200/jco.24.00081 ↗
Michael James Overman · 1 shared paper, 2024 · strength 0.16
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0 ↗
Abdelrahman M.G. Yousef · 1 shared paper, 2024 · strength 0.16
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0 ↗
Saikat Chowdhury · 1 shared paper, 2024 · strength 0.16
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0 ↗
Huamin Wang · 1 shared paper, 2024 · strength 0.16
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0 ↗
Kawther Abdilleh · 1 shared paper, 2024 · strength 0.16
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0 ↗
Mahmoud Yousef · 1 shared paper, 2024 · strength 0.16
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0 ↗
Rebecca Anne Snyder · 1 shared paper, 2024 · strength 0.16
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0 ↗
Anirban Maitra · 1 shared paper, 2024 · strength 0.16
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0 ↗
Sudheer Doss · 1 shared paper, 2024 · strength 0.16
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0 ↗
Lynn McCormick Matrisian · 1 shared paper, 2024 · strength 0.16
- Paper Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. DOI 10.1038/s41698-024-00505-0 ↗
Suyu Liu · 1 shared paper, 2024 · strength 0.15
- Paper Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEN… DOI 10.1200/jco.24.00081 ↗
Albert C. Koong · 1 shared paper, 2024 · strength 0.15
- Paper Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEN… DOI 10.1200/jco.24.00081 ↗
Alexander Dean Sherry · 1 shared paper, 2024 · strength 0.15
- Paper Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEN… DOI 10.1200/jco.24.00081 ↗
Grace L. Smith · 1 shared paper, 2024 · strength 0.15
- Paper Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEN… DOI 10.1200/jco.24.00081 ↗
Chad Z. Tang · 1 shared paper, 2024 · strength 0.15
- Paper Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEN… DOI 10.1200/jco.24.00081 ↗
Cullen M. Taniguchi · 1 shared paper, 2024 · strength 0.15
- Paper Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEN… DOI 10.1200/jco.24.00081 ↗
Ethan Bernard Ludmir · 1 shared paper, 2024 · strength 0.15
- Paper Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEN… DOI 10.1200/jco.24.00081 ↗
Eugene Jon Koay · 1 shared paper, 2024 · strength 0.15
- Paper Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEN… DOI 10.1200/jco.24.00081 ↗
Ryan W. Huey · 1 shared paper, 2024 · strength 0.15
- Paper Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEN… DOI 10.1200/jco.24.00081 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.